Share on StockTwits
 

Neurocrine Biosciences (NASDAQ:NBIX) Insider Dimitri E. Grigoriadis sold 25,000 shares of the stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $20.00, for a total transaction of $500,000.00. Following the transaction, the insider now directly owns 77,058 shares of the company’s stock, valued at approximately $1,541,160. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

A number of research firms have recently commented on NBIX. Analysts at Nomura initiated coverage on shares of Neurocrine Biosciences in a research note to investors on Wednesday, January 8th. They set a “buy” rating on the stock. Separately, analysts at Morgan Stanley downgraded shares of Neurocrine Biosciences from an “overweight” rating to an “equal weight” rating in a research note to investors on Wednesday, January 8th. They now have a $16.00 price target on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Neurocrine Biosciences from $16.00 to $23.00 in a research note to investors on Wednesday, January 8th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $18.73.

Shares of Neurocrine Biosciences (NASDAQ:NBIX) traded down 1.48% on Tuesday, hitting $19.36. The stock had a trading volume of 905,918 shares. Neurocrine Biosciences has a 1-year low of $8.57 and a 1-year high of $20.29. The stock’s 50-day moving average is $12.02 and its 200-day moving average is $12.15. The company’s market cap is $1.304 billion.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Tuesday, October 29th. The company reported ($0.17) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.20) by $0.03. The company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.79 million. During the same quarter in the prior year, the company posted ($0.05) earnings per share. The company’s quarterly revenue was down 92.2% on a year-over-year basis. Analysts expect that Neurocrine Biosciences will post $-0.70 EPS for the current fiscal year.

Neurocrine Biosciences, Inc (NASDAQ:NBIX) discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.